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Background: Second generation bare metal stents made of cobalt chromium alloy are su-
perior to first generation stain less steel stents. The thin struts are shown to reduce clinical
and angiographic adverse outcomes.
Objective: To study the long term clinical and angiographic outcomes in patients who un-
derwent coronary angioplasty with an indigenously made cobalt chromium bare metal
stents with thin strut CobalþC™ (Relisys).
Methods: A total of 268 consecutive patients who underwent coronary angioplasty with
CobalþC stents were studied retrospectively. Clinical follow up was done after a minimum
period of nine months through telephonic interview and angiographic follow up was done
in 80 patients chosen randomly. The end points analyzed included major adverse cardiac
events (MACE) at nine months and the rate of binary restenosis at follow up angiogram
done between 9 and 15 months post angioplasty.
Results: Thirty four percent were diabetic and 33% had acute myocardial infarction. Fe-
males constituted 17%. Mean stent diameter was 2.88 ± 0.28 and mean stent length
18.8 ± 4.2. MACE at nine months was 4.5% with TLR 0.3%. The rate of binary restenosis was
21%. Patients with longer stent lengths and non-compliance with medications had
significantly higher rates of binary restenosis.
Conclusions: The use of Relisys CobalþC stents was associated with good long term clinical
and angiographic outcomes as evidenced by low incidence of MACE and binary restenosis
rates for a bare metal stent.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
Despite the overwhelming popularity of drug eluting stents
(DES),1 bare metal stents (BMS) continue to be used in about
30% of patients due to various reasons. The most common8.
B.K.S. Sastry).
ociety of India. All rightsreason to use BMS in our country is financial constraints. The
clinical and angiographic conditions that are likely to be
benefited more by the use of BMS include planned surgical
procedure within six months of angioplasty and bleeding
disorders which might hamper the treatment with dualreserved.
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larger vessels.
Surprisingly the existing publications on cobalt chromium
stents are scant. These are mainly prospectively controlled
observational studies done in highly selected patient popula-
tion using limited stent sizes and lengths and angiography
done at the end of six months. Some information about their
performance can also be obtained from the randomized clin-
ical trials in which these BMS are used as comparator against
DES.
In the initial stages of its usage, themajor limitation of BMS
made of stainless steel was acute stent thrombosis and the
high incidence of restenosis.2e6 The safety and efficacy of
stents with thin struts was realized.7e10 Stents made of cobalt
chromium alloy have been specifically developed since it is
stronger and denser than stainless steel. These properties
make it possible to design stents with thinner struts while
maintaining radial strength and also radio opacity. The new
designs with thinner struts contributed to lesser vessel dam-
age and faster and complete endothelialization and better
outcomes.
CobalþC is an indigenously developed stent manufactured
by Relisys, Mangalpally, Telangana, India. It is a cobalt chro-
mium coronary stent with ultra thin strut thickness 0.002900
compared to 0.003200 of Vision stent (Abbott Vascular, Illinois,
USA) and 0.003600 of Driver stents (Medtronic, Minneapolis,
USA). It has superior surface smoothness due to a patented
and improved electro polishing technology. As shown by the
Atomic Force Microscopic study, the Root Mean Square (RMS)
surface roughness of the CobalþC stent is 3.22 nm which is
37% lower than that of Driver stent (5.12 mm) (Data on file in
Relisys). It has been in clinical use for the past seven years.We
planned to study the long term safety and efficacy of CobalþC
stents in real world situation.
1.1. Objective
To study the long term clinical and angiographic outcomes in
patients who underwent percutaneous coronary intervention
with CobalþC stents.2. Methodology
This is a retrospective study conducted in consecutive pa-
tients who underwent CobalþC stent implantation at CARE
Hospitals, Banjara Hills and Nampally in Hyderabad from
January 2009 to May 2010. Patients in whom stents other than
CobalþC were used in conjunction were not included for the
study. This is an all comer study and the indication for the
angioplasty procedure and technique of stent implantation
were as per the discretion of the treating physician. All pa-
tients were advised dual antiplatelet therapy with clopidogrel
and aspirin. Patients who were not pre-treated received a
bolus dose of 300mg of clopidogrel and 325mg soluble aspirin
just before the procedure.
Telephonic follow up using structured questionnaires
developed for this study was done at a minimum period of 9
months post stent implantation by study coordinators.
Angiographic follow up was performed in 80 randomlyselected patients. They were invited to have coronary angio-
gram. Follow up coronary angiogramwas done between 9 and
15 months after the index procedure with a median of 12
months. Two of the authors had independently assessed bi-
nary restenosis by visual assessment. Inter observer variation
was resolved by consensus.
For the purpose of this study, major adverse cardiac events
(MACE) was defined as a Composite of cardiac death,
myocardial infarction [Q wave and non Q wave (CK-
MB > 5  upper limit of normal)], emergency bypass surgery,
or repeat target vessel revascularization (TLR) at 9e15 months
post stent implantation. Rate of binary restenosis was defined
as the percent of patients with a percent in-stent or in
segment diameter stenosis of 50% in check angiogram per-
formed at 9e15 months post stent implantation.
2.1. Statistical analysis
Continuous variables are reported as means and standard
deviations. Categorical variables are reported as numbers
(percentages). Statistical analysis was limited to comparisons
of groups who had binary restenosis with those who did not.
Fischer Exact test was used for categorical variables and two
tailed Student's T-test was used for continuous variables.3. Results
Within the study period, a total of 268 patients 182 from CARE
hospital, Banjara Hills and 86 from CARE Hospital, Nampally
were treatedwith CobalþC stents. Among these patients, only
261 could be contacted for follow up assessment while 7 of the
total cohort could not be contacted.
3.1. Baseline characteristics
The age of patients ranged from 30 to 88 yrs and females were
17%. Thirty one percent were diabetic. Acute MI and unstable
angina were the clinical indication for 33% and 61% patients.
The baseline demographics are shown in Table 1 and baseline
clinical and angiographic profile in Table 2.
3.2. Angiography and angioplasty details
Three hundred and fourteen stents were implanted in 283
vessels of 261 patients. Ninety percent of patients had single
vessel coronary artery disease. Stent dimensions ranged from
2.5 mm to 3.5 mm in diameter and 10 mme32 mm in length.
The mean stent diameter was 2.88 ± 0.28 and mean stent
length 18.8 ± 4.21. Angiographic success was achieved in all
patients.
3.3. Clinical follow up
Seventeen patients had died after the index procedure of
which 11were due to cardiac causes (4.2%) and six were due to
non cardiac causes. Six of the cardiac deaths were in hospital
in patients undergoing primary angioplasty for acute
myocardial infarction. After discharge two deaths occurred in
patients with severe left ventricular dysfunction, while three
Table 1 e Baseline demographics and clinical
characteristics.
Total no. of patients 261a
Age (range in yrs) 30e88
Female gender 45 (17%)
Diabetes 90 (34%)
Hypertension 135 (52%)
Current smoking 96 (37%)
Previous PCI None
Previous CABG 1 (0.38%)
CABG ¼ coronary artery bypass grafting; PCI ¼ percutaneous cor-
onary intervention.
a 7 of the total 268 consecutive patients were lost to follow up.
Table 3 e Clinical follow up.
MACE 12 (4.5%)
All cause mortality 17 (6.5%)
Death due to cardiac cause 11 (4.2%)
Sub acute thrombosis 0 (0%)
TLR (with CABG) 1 (0.3%)
Repeat PCI of the target vessel 0 (0%)
Non-compliance with medications 33 (12.5%)
Continued smoking 42 (16%)
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after a period of three months. Further details in these late
deaths were not available. One patient had TLR with CABG.
Twelve patients had MACE. No patient in this cohort pre-
sented to our hospital with sub acute thrombosis or stroke or
angina requiring repeat percutaneous coronary intervention.
In more than three fourth of the patients who had MACE,
acute MI was the clinical indication for angioplasty. Nearly
67% of them were diabetic and two had severe LVD (Table 3).
3.4. Angiographic follow up
Follow up angiogram was done in 80 patients (30%) from 9 to
15 months with a median of 12 months following the initial
procedure. Of these 80 patients, 26% of patients continued to
be active smokers and 30% were not compliant with medica-
tions including antiplatelet drugs and statins at the time of
follow up (Table 4). Drug compliance was for variable period ofTable 2 e Baseline, clinical and angiographic
characteristics.
Clinical indications
Total number of patients 261a
AMI 86 (33%)
Unstable angina 174 (66%)
Stable angina 3 (1%)
Severe LV dysfunction 24 (9%)
Total no. of target vessels 283
Single vessel disease 238 (90%)
Two vessel disease 25 (10%)
Target vessels (n ¼ 283)
LAD 131 (46%)
LCX 39 (14%)
RCA 99 (35%)
OM 12 (4%)
Ramus 1 (0.35%)
LIMA 1 (0.35%)
SVG 1 (0.35%)
Total no. of stents 314
Stent diameter (mean ± SD) 2.88 ± 0.28
Stent length (mean ± SD) 18.8 ± 4.21
Angiographic success 261 (100%)
AMI ¼ Acute myocardial infarction; LV ¼ Left ventricle; LAD ¼ Left
anterior descending artery; LCX ¼ Left circumflex artery;
RCA ¼ Right coronary artery; OM ¼ Obtuse marginal; LIMA ¼ Left
internal mammary artery; SVG ¼ Saphenous vein graft.
a 7 of the total 268 consecutive patients were lost to follow up.time. Binary restenosis was found in 17 patients (21%). In this
group with restenosis, 71% were not compliant with medica-
tions while 41%were diabetic and 35% continued to smoke, all
known risk factors for restenosis. The mean stent diameter
was significantly less in this group compared to those without
restenosis (2.75 ± 0.16 Vs 2.9 ± 0.3 mm p < 0.03). Similarly
mean stent length was significantly more in this group
compared to those without restenosis (21.6 ± 5.6 mm V
18.3 ± 4.2 p < 0.005) (Table 5).4. Discussion
In this retrospective study which reflected the real world sit-
uation, indigenously manufactured cobalt chromium stent
CobalþC was comparable to published data with other cobalt
chromium stents.
This all comer retrospective study with a median follow up
period of 12 months cannot be compared directly with any
prospective registry or a randomized controlled trial. There
are both positive and negative aspects to this kind of analysis.
In a prospective registry structured follow up of patients
would lead to better adherence of medication and life style
changes like quitting smoking habit. These in turn would lead
to better patient outcomes. In a randomized controlled trial
patient enrollment is often selective and treatment and follow
up are well controlled. The kind of close monitoring itself
would affect the outcomes as it is noted that patients in ran-
domized controlled trials tend to have better outcomes than
patients in real world situation. Unless it is an all comer trial,
the data would not be applicable to all the patients. The
retrospective analysis of our patient cohort truly represents
real world situation as it exists in our circumstances.
In this cohort, patients with acute myocardial infarction
were 33%, stents less than 3mmdiameter were used in 56% ofTable 4 e Baseline characteristics of patients with
angiographic follow up.
No of patients who had follow up angiogram 80
Female gender 10 (12.5%)
Current smokers 21 (26.2%)
Non-compliance with medications 24 (30%)
Diabetes mellitus 25 (31.2%)
Systemic hypertension 42 (52.5%)
Indications for angioplasty
AMI 29 (36.2%)
Unstable angina 49 (61.2%)
Stent diameter (mean ± SD) 3 ± 0.294
Stent length (mean ± SD) 19.07 ± 4.73
Binary restenosis 17 (21.2%)
Table 5 e Comparison of clinical, angiographic and procedural characteristics of patients with and without binary
restenosis.
With binary stenosis (n ¼ 17)
Total no. of stents ¼ 21
Without binary stenosis (n ¼ 63)
Total no. of stents ¼ 71
p Value
Indications for PCI
Acute MI 6 (35.2%) 24 (34%) NS
Unstable angina 11 (64.7%) 38 (54%) NS
Risk factors
Diabetes mellitus 7 (41%) 18 (25%) NS
Hypertension 9 (52.9%) 33 (46%) NS
Active smoking 6 (35.2%) 15 (21%) NS
Drug non-compliance 12 (70.5%) 12 (17%) 0.0001
Stent diameter in mm (mean ± SD) 2.75 ± 0.16 2.9 ± 0.3 0.03
Stent length in mm (mean ± SD) 21.6 ± 5.6 18.3 ± 4.2 0.0051
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16% of patients continued to smoke and 13% pf patients
stopped all medication. All these factors would adversely
affect the clinical outcomes and restenosis rates.11e13 Even
then, the observed results are good for a bare metal stent. It
can be assumed that the clinical and angiographic outcomes
would have been even better if we had used stringent clinical,
angiographic inclusion and exclusion criteria, and used only
stents with certain dimensions and followed these patients
prospectively ensuring adherence to medication and life style
changes as done in published clinical trials of other BMS.
The MACE rate of 4.5% and lower TLR rate of 0.3% are
comparable to other published reports of cobalt chromium
stents. In prospective studies MACE at six months ranged
from 5.7% to 10.6% and TLR from 3.4% to 9.8%.14e17 Higher
mortality and lower TLR in our study reflect the kind of patient
population that included 37% with acute myocardial infarc-
tion undergoing primary angioplasty.
Binary restenosis rate was 21% at an average of 12 months,
and it compares well with other cobalt chromium stents. In
Endeavor II trial the reported binary restenosis rate at the end
of 8months in Driver stent armwas 35%.18 Patients with acute
MI were not included in these studies. Moreover, the results
were of eight months post angioplasty compared to median
time of 12 months for angiography in our study. In other trials
done using Driver stent 3 mm in diameter the six month
angiograohic restenosis rates varied from 15 to 26% in select
patients.19 More than 50% of our patients had <3.0 mm stents
implanted which correlates strongly with restenosis. It is
interesting to note that with Driver stents, the TLR at six
months was 3.4% whereas; at nine months it almost
doubled.19
In a prospective real world study involving Asian popula-
tion using Coroflex stent the binary restenosis rate was 47.5%
at six months.15 Though the study involved complex lesions
and acute MI patients and stents smaller than 3.0 mm were
used like in our study, it had excluded lesion lengths of
>25 mm. In our study, stent sizes of length >24 mm consti-
tuted 18% and this subset with longer stent length has higher
restenosis rates.
The cobalt chromium Vision and Minivision stent study
which included real-world population like our study had
shown comparable restenosis rates. The restenosis rate at six
months with Vision and Minivision stents were 17.9% and
45.5% respectively. Together, the restenosis rate was 30%.20Poor compliance with medication is a well known phe-
nomenon in the developing countries and 13% percent of our
total cohort had discontinued anti-platelets which is unlikely
in any other prospective study. Among the patients with bi-
nary restenosis 71% stopped antiplatelet agents. This differ-
ence was found to be significant when compared with
patients who did not have binary restenosis. Physicians have
to be vigilant about this and caution their patients accord-
ingly. This kind of adversely influencing data was not looked
into/or reported in other published studies using other cobalt
chromium stents.
There are certain limitations to this study. Besides being a
non-randomized and retrospective study, it was done from
only two centres and angiographic core lab analysis was not
done. It cannot be commented if similar results will be
reproduced in a multi centre study. Lesion characteristics in-
fluence the outcomes of procedures but, they were not stud-
ied. The safety and efficacy of this stent in treating lesions in
LMCA and coronary bypass grafts could not be ascertained as
there was only one patient in each of these.
It may be concluded that though this is not a head to head
comparative study with other stents, CobalþC™ stent was
found to have good long term clinical and angiographic out-
comes. This is in spite of presence of multiple adversely
influencing factors. Direct comparative studies will give better
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